Innoforce Pharmaceuticals Co., Ltd. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2018

Location

Hangzhou China

Primary Industry

Pharmaceuticals

About

Based in Hangzhou, China and founded in 2018, Innoforce Pharmaceuticals Co., Ltd. operates as a biopharmaceutical company that develops innovative medicines, operation management, and other supports for healthcare enterprises. The company was founded by Dr. Guo-Liang Yu and Dr. Yuling. In March 2021, Innoforce Pharmaceuticals raised CNY 625 million (USD 96 million) in series A funding from Quan Capital, South China Venture Capital, and Yanyuan Capital. The company has a biopharmaceutical manufacturing facility and research lab for monoclonal antibodies with international GMP standards, recombinant protein, plasmid DNA, viral vector, cell, and gene therapy. Its gene and cell therapy products affect markets in China, the US, Europe, and the rest of the world. Innoforce Pharmaceuticals Co., Ltd. plans to use the funding raised in March 2021 to advance the development of INF’s campus in Hangzhou, China, and continue to build its product development, operations management, and general support for entrepreneurial companies.

Current Investors

South China Venture Capital, Quan Capital, Quan Capital

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Biopharmaceuticals, Pharmaceutical Research & Development

Website

www.innoforce.com.cn

Verticals

HealthTech

Company Stage

Series A

Total Amount Raised

Subscriber access only

Key Contacts

Name	Position	Start Date	End Date	Vcard	Bio
	Chief Executive Officer						BM

BM Board Member

Name	Firm	Deal Date	Number Of Deals	Vcard
						AI LP
						AI LP

AI Active Investor LP Lead Provider

Want to see more?

Request a demo for full access to this profile.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.